Anti-interleukin-5 therapy and severe asthma [1]

New England Journal of Medicine

Volumn 360, Issue 24, 2009, Pages 2576-2578

  Zarogiannis, Sotirios ^a   Gourgoulianis, Konstantinos I ^a   Kostikas, Konstantinos ^a  

^a UNIVERSITY OF THESSALY   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 5 ANTIBODY; MEPOLIZUMAB; INTERLEUKIN 5; MONOCLONAL ANTIBODY; ACETYLSALICYLIC ACID; NONSTEROID ANTIINFLAMMATORY AGENT;

AIR POLLUTION; AIR QUALITY; ASTHMA; EOSINOPHIL; HUMAN; LETTER; PRIORITY JOURNAL; UNITED KINGDOM; WORLD HEALTH ORGANIZATION; DRUG ANTAGONISM; EOSINOPHILIA; NOTE; RECURRENT DISEASE; CLASSIFICATION; PHENOTYPE; DISEASE SEVERITY; DRUG EFFECT; PROVOCATION TEST;

AIR POLLUTION; ANTIBODIES, MONOCLONAL; ASTHMA; EOSINOPHILIA; HUMANS; INTERLEUKIN-5; RECURRENCE; ASPIRIN; PHENOTYPE;

EID: 67249087537     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMc090685     Document Type: Letter

References (5)

1. Haldar P, Brightling CE, Hargadon B, et al. Mepolizumab and exacerbations of refractory eosinophilic asthma. N Engl J Med 2009;360:973-984
2. Leicester Air Quality Monitoring Network. Leicester, UK: Leicester City Council. (Accessed May 21, 2009, at http://rcweb.leicester.gov.uk/pollution/asp/ home.asp.)
3. Künzli N, Perez L, Lurmann F, Hricko A, Penfold B, McDonnell R. An attributable risk model for exposures assumed to cause both chronic disease and its exacerbations. Epidemiology 2008;19:179-185
4. Air quality guidelines: global update. Geneva: World Health Organization, 2005:217-280
5. McCreanor J, Cullinan P, Nieuwenhuijsen MJ, et al. Respiratory effects of exposure to diesel traffic in persons with asthma. N Engl J Med 2007;357:2348-2358